Most commercial laboratories offer limited or no testing for hereditary lung cancer variants, and no guideline has been established for the best way to manage unaffected carriers of variants associated with lung cancer, such as germline EGFR T790M, HER2 and YAP1 mutations. Here, EGFR is linked to lung cancer.